As of November 14, 2026, retatrutide has no FDA-approved product in the United States. The FDA says it cannot be used in compounding under federal law and has warned companies about marketing it directly to consumers.[3] The guide to compounded GLP-1 sourcing explains which pharmacy details can be verified for other medications. A pharmacy name on an advertised retatrutide vial does not establish its contents or safety.
What the peer-reviewed phase 3 trial found
TRIUMPH-1 randomly assigned 2,339 adults with obesity and without diabetes to retatrutide or placebo for 80 weeks. In the trial’s main weight analysis, the estimated mean weight losses were 17.6%, 23.7%, and 25.0% in the 4 mg, 9 mg, and 12 mg groups and 3.9% with placebo. The analysis assessed participants by assigned treatment group. Gastrointestinal side effects were the most common. Eli Lilly funded the trial.[2]
For readers comparing weight-loss estimates across treatments, the comparator, the participants’ health conditions, and follow-up time affect how to read each result. TRIUMPH-1 compared retatrutide with placebo in adults without diabetes. Separately, in October 2026 Lilly released topline results from TRANSCEND-T2D-2, an open-label comparison with injectable semaglutide 2 mg in adults with type 2 diabetes. That source is a sponsor announcement for a different study.[2][4]
What the earlier phase 2 trial adds
The phase 2 trial randomized 338 adults with obesity or overweight and a weight-related condition. At week 48, estimated average weight loss was 8.7% in the 1 mg group, 17.1% in the combined 4 mg group, 22.8% in the combined 8 mg group, and 24.2% in the 12 mg group, compared with 2.1% with placebo.[1]
Gastrointestinal side effects were dose-related and mostly mild to moderate. Increases in heart rate also varied by dose, peaked at 24 weeks, and declined afterward. The trial was funded by Eli Lilly.[1]
What the trial results mean for products advertised online
These results describe the drug supplied and monitored in clinical trials. They cannot verify the identity, strength, or safety of a vial advertised online. FDA warns consumers against purchasing products sold for human use under labels such as “for research purposes.”[3]